Comparison of HTLV-I Proviral Load in Adult T Cell Leukemia/Lymphoma (ATL), HTLV-I-Associated Myelopathy (HAM-TSP) and Healthy Carriers

Document Type: Original Article

Authors

1 Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran

2 Inflammation and inflammatory research centre, Medical School, Mashhad University of Medical Science, Mashhad- Iran 2 Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran

3 Internal Medicine Dept, Amir al Moemenin Hospital, Arak University of Medical Sciences.

4 Internal medicine Dept. Medical School, Mashhad University of Medical Science, Mashhad- Iran

5 Navid Medical Lab, Mashhad- Iran

Keywords


Gallo RC. History of the discoveries of the first human retroviruses:

HTLV-I and HTLV-II. Oncogene 2005; 24:5926-30. Epub

2005/09/13.

2. Yamashiro T, Kamiya H, Miyara T, Gibo S, Ogawa K, Akamine T,

 

et

al.

 

 

 

CT scans of the chest in carriers of human T-cell lymphotropic

virus type 1: presence of interstitial pneumonia. Acad Radiol

 

2012; 19:952-957. Epub 2012/05/15.

 

3. Naderi M, Paryan M, Azadmanesh K, Rafatpanah H, Rezvan H,

 

Mirab Samiee S. Design and development of a quantitative

 

real time PCR assay for monitoring of HTLV-I provirus in whole

 

blood. Journal of clinical virology : the official publication of the

 

Pan American Society for Clinical Virology. 2012; 53:302-307. Epub

 

2012/02/07.

 

4. Trevino A, Aguilera A, Caballero E, Benito R, Parra P, Eiros JM,

 

 

 

et al.

 

Trends in the prevalence and distribution of HTLV-I and HTLV-II

infections in Spain. Virol J 2012; 9:71. Epub 2012/03/27.

5. Sadeghian MH, Keramati MR, Ayatollahi H, Feizabadi AS, Tehranaian

F, Shakibyee H. Is there any relationship between expressions

of minor blood group antigens with HTLV-I infection?

Transfusion and apheresis science : official journal of the World

Apheresis Association : official journal of the European Society

for Haemapheresis. Transfus Apher Sci 2012; 47:151-154. Epub

2012/08/04.

6. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F,

Bidkhori HR, Shamsian SK, Ahmadi S,

et al.

High prevalence of

HTLV-I infection in Mashhad, Northeast Iran: a population-based

 

seroepidemiology survey. Journal of clinical virology : the official

 

publication of the Pan American Society for Clinical Virology.

 

J Clin Virol 2011; 52:172-176. Epub 2011/08/16.

 

7. Azarpazhooh MR HK, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-

 

Moghaddam MR, Valizadeh N

 

 

, et al

. Human T-lymphotropic

virus type 1 prevalence in northeastern Iran, Sabzevar: an

 

epidemiologic-based study and phylogenetic analysis. AIDS Res

 

Hum Retroviruses 2012; 28:1095-10101.

 

8. Saito M. Immunogenetics and the Pathological Mechanisms

 

of Human T-Cell Leukemia VirusType 1- (HTLV-I-)Associated Myelopathy/

 

Tropical Spastic Paraparesis (HAM/TSP). Interdiscip Perspect

 

Infect Dis 2010; 2010:478461. Epub 2010/02/20.

 

9. Abdelbary NH, Abdullah HM, Matsuzaki T, Hayashi D, Tanaka

 

Y, Takashima H,

 

 

et al.

Reduced Tim-3 expression on human Tlymphotropic

virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes

 

in HTLV-I infection. J Infect Dis 2011; 203:948-959. Epub

 

2011/03/16.

 

10. Cabrera ME, Labra S, Catovsky D, Ford AM, Colman SM, Greaves

 

MF,

 

 

et al.

HTLV-I positive adult T-cell leukaemia/lymphoma (ATLL)

in Chile. Leukemia 1994; 8:1763-1767. Epub 1994/10.01/

 

11. Ceesay MM, Matutes E, Taylor GP, Fields P, Cavenagh J, Simpson S,

 

 

et al

. Phase II study on combination therapy with CHOP-Zenapax

for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).

 

Leukemia Res 2012; 36:857-861. Epub 2012/01/03.

 

12. Kokoris SI, Siakantaris MP, Kontopidou FN, Kyrtsonis MC, Tsakris

 

A, Spanakis N,

 

 

et al.

Adult T-cell leukemia/lymphoma (ATLL): report

of two fully documented Hellenic patients. Leukemia Lymphoma

 

2004; 45:715-21. Epub 2004/05/27.

 

13. Costa DT, Sundberg M, Passos L, Muniz AL, Santos S. Interferon

 

Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and

 

Modifies the Immune Response in a Patient with HAM/TSP. Case

 

Rep Neurol Med 2012; 2012:958786. Epub 2012/09/07.

 

14. Cabral F ,Arruda LB, de Araujo ML, Montanheiro P, Smid J, de

 

Oliveira AC,

 

 

et al.

Detection of human T-cell lymphotropic virus

type 1 in plasma samples. Virus Res 2012; 163:87-90. Epub

 

2011/09/20.

 

15. Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr

 

L,

 

 

et al.

The impact of interferon-alpha treatment on clinical

and immunovirological aspects of HTLV-I-associated myelopathy

 

in northeast of Iran. J Neuroimmunol 2012; 250:87-93. Epub

 

2012/06/26.

 

16. Currer R, Van Duyne R, Jaworski E, Guendel I, Sampey G, Das R,

 

 

et al

. HTLV tax: a fascinating multifunctional co-regulator of

viral and cellular pathways. Front Microbiol 2012; 3:406. Epub

 

2012/12/12.

 

17. Leal FE, Ndhlovu LC, Hasenkrug AM, Bruno FR, Carvalho KI,

 

Wynn-Williams H,

 

 

et al

. Expansion in CD39(+) CD4(+) Immunoregulatory

T Cells and Rarity of Th17 Cells in HTLV-I Infected Patients

 

Is Associated with Neurological Complications. PLoS Negl

 

Trop Dis 2013; 7:e2028. Epub 2013/02/15.

 

18. Yamano Y, Sato T .Clinical pathophysiology of human T-lymphotropic

 

virus-type 1-associated myelopathy/tropical spastic para

 

 

 

219

 

HTLV-I proviral load in ATL, HAM-TSP and healthy carriers Akbarin MM R et al

Iran J Basic Med Sci; Vol. 16, No. 3, Mar 2013

paresis. Front Microbiol 2012; 3:389. Epub 2012/11/20.

19. Tsukasaki K, Imaizumi Y, Tawara M, Fujimoto T, Fukushima T,

Hata T,

et al

. Diversity of leukaemic cell morphology in ATL correlates

with prognostic factors, aberrant immunophenotype and

 

defective HTLV-I genotype. Br J Haematol 1999; 105:369-375. Epub

 

1999/05/08.

 

20. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A ,Uchimaru K,

 

Koh KR,

 

 

et al

. Human T-cell leukemia virus type I (HTLV-I) proviral

load and disease progression in asymptomatic HTLV-I carriers: a

 

nationwide prospective study in Japan. Blood 2010; 116:1211-1219.

 

Epub 2010/05/08.

 

21. Taylor GP TJ, Matutes E. Prospective study of HTLV-I infection in

 

an initially asymptomatic cohort. J Acquir Immune Defic Syndr

 

1999; 22:92-100.

 

22. Kchour G, Tarhini M, Kooshyar MM, El Hajj H, Wattel E, Mahmoudi

 

M,

 

 

et al.

Phase 2 study of the efficacy and safety of the combination

of arsenic trioxide, interferon alpha, and zidovudine in

 

newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

 

Blood 2009; 113:6528-6532. Epub 2009/05/05.

 

23. Nasr R, El Hajj H, Kfoury Y, de The H, Hermine O, Bazarbachi A.

 

Controversies in targeted therapy of adult T cell leukemia/lymphoma:

 

ON target or OFF target effects? Viruses 2011; 3:750-769.

 

Epub 2011/10/14.

 

24. Uozumi K. Treatment of adult T-cell leukemia. J Clin Exp Hematopathol

 

2010 .25-50:9 ;Epub 2010/05/28.

 

25. Nagai M UK, Matsumoto W, Kodama D, Takenouchi N, Moritoyo

 

T. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and

 

243 asymptomatic HTLV-I carriers: high proviral load strongly

 

predisposes to HAM/TSP. J Neurovirol 1998; 4:586-593.

 

26. Adaui V, Verdonck K, Best I, Gonzalez E, Tipismana M, Arevalo J,

 

 

et al.

SYBR Green-based quantitation of human T-lymphotropic

virus type 1 proviral load in Peruvian patients with neurological

 

disease and asymptomatic carriers: influence of clinical status,

 

sex ,and familial relatedness. J Neurovirol 2006; 12:456-465. Epub

 

2006/12/13.

 

27. Montanheiro P, Olah I, Fukumori LM, Smid J, Oliveira AC, Kanzaki

 

LI,

 

 

et al.

Low DNA HTLV-II proviral load among women in Sao Paulo

City. Virus Res 2008;135:22-25. Epub2008/03/18.